Apogee Therapeutics Inc.
Apogee Therapeutics Announces Positive Phase 1 Trial Results for APG777
Summary
Apogee Therapeutics, Inc. announced updated positive results from its ongoing Phase 1 clinical trial of APG777, its novel half-life extended anti-IL-13 antibody for the treatment of atopic dermatitis and other inflammatory diseases, in healthy volunteers up to nine months. The trial demonstrated a well-tolerated safety profile and pharmacokinetic data supporting a potential best-in-class profile, including a half-life of approximately 75 days. Pharmacodynamic data showed near complete inhibition of pSTAT6 and sustained TARC inhibition up to 9 months. Proof-of-concept data from the Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis are expected in the second half of 2025.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement